Zinda Michael
EVP, CHIEF SCIENTIFIC OFFICER at Repare Therapeutics Inc.
- Sold, on record
- $6.7M
- Dollars the filings state
- Form 4 sales
- 13
- Latest Mar 12, 2025
- Form 144 notices
- 2
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- Repare Therapeutics Inc.EVP, CHIEF SCIENTIFIC OFFICER
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale Repare Therapeutics Inc.Plan not statedMar 15 2022
Sold 533 shares at $11.30 ($6k)
Zinda Michael, EVP, Chief Science Officer
Sold 1.1% of holdings ($526k position)46,041 shares left0x usual sizeFiling
- 2 Form 144 notice Repare Therapeutics Inc.NoticeJun 6 +448 days
Filed to sell 10,473 shares ($123k)
Zinda Michael, Officer
10b5-1 plan0.7x usual sizeFiling
- 3 Form 4 sale Repare Therapeutics Inc.RoutineJun 6 same day
Sold 1,200 shares at $12.04 ($14k)
Zinda Michael, EVP, Chief Scientific Officer
10b5-1 planSold 1.7% of holdings ($850k position)69,391 shares left0.1x usual sizeFollows a Form 144Filing
- 4 Form 4 sale Repare Therapeutics Inc.RoutineJun 7 +1 day
Sold 6,404 shares at $12.03 ($77k)
Zinda Michael, EVP, Chief Scientific Officer
10b5-1 planSold 9.2% of holdings ($835k position)62,987 shares left0.8x usual sizeFollows a Form 144Filing
- 5 Form 144 notice Repare Therapeutics Inc.NoticeMar 25 +292 days
Filed to sell 2,210 shares ($11k)
Zinda Michael, Officer
10b5-1 planFiling
- 6 Form 4 sale Repare Therapeutics Inc.RoutineMar 27 +2 days
Sold 1,350 shares at $4.67 ($6k)
Zinda Michael, EVP, CHIEF SCIENTIFIC OFFICER
10b5-1 planSold 1.8% of holdings ($346k position)72,768 shares leftFollows a Form 144Filing
- 7 Form 4 sale Repare Therapeutics Inc.RoutineApr 1 +5 days
Sold 860 shares at $4.65 ($4k)
Zinda Michael, EVP, CHIEF SCIENTIFIC OFFICER
10b5-1 planSold 1.2% of holdings ($338k position)71,908 shares left0.6x usual sizeFollows a Form 144Filing
- 8 Form 4 sale Repare Therapeutics Inc.UnusualMar 12 +345 days
Sold 5,611 shares at $1.14 ($6k)
Zinda Michael, EVP, CHIEF SCIENTIFIC OFFICER
No 10b5-1 planSold 6.5% of holdings ($98k position)80,297 shares left4.4x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (15)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Mar 12, 2025 | Repare Therapeutics Inc. | EVP, CHIEF SCIENTIFIC OFFICER | Form 4 sale | 5,611 | $6k | 6.5% | Unusual | SEC |
| Apr 1, 2024 | Repare Therapeutics Inc. | EVP, CHIEF SCIENTIFIC OFFICER | Form 4 sale | 860 | $4k | 1.2% | Routine | SEC |
| Mar 27, 2024 | Repare Therapeutics Inc. | EVP, CHIEF SCIENTIFIC OFFICER | Form 4 sale | 1,350 | $6k | 1.8% | Routine | SEC |
| Mar 25, 2024 | Repare Therapeutics Inc. | Officer | Form 144 notice | 2,210 | $11k | Notice | SEC | |
| Jun 7, 2023 | Repare Therapeutics Inc. | EVP, Chief Scientific Officer | Form 4 sale | 6,404 | $77k | 9.2% | Routine | SEC |
| Jun 6, 2023 | Repare Therapeutics Inc. | EVP, Chief Scientific Officer | Form 4 sale | 1,200 | $14k | 1.7% | Routine | SEC |
| Jun 6, 2023 | Repare Therapeutics Inc. | Officer | Form 144 notice | 10,473 | $123k | Notice | SEC | |
| Mar 15, 2022 | Repare Therapeutics Inc. | EVP, Chief Science Officer | Form 4 sale | 533 | $6k | 1.1% | Plan not stated | SEC |
| Nov 15, 2021 | Repare Therapeutics Inc. | EVP, Chief Science Officer | Form 4 sale | 20,000 | $547k | 97.4% | Unusual | SEC |
| Aug 16, 2021 | Repare Therapeutics Inc. | EVP, Chief Science Officer | Form 4 sale | 15,000 | $510k | 42.2% | Unusual | SEC |
| May 17, 2021 | Repare Therapeutics Inc. | EVP, Chief Science Officer | Form 4 sale | 15,000 | $491k | 29.7% | Unusual | SEC |
| Dec 29, 2020 | Repare Therapeutics Inc. | EVP, Chief Science Officer | Form 4 sale | 34,744 | $1.2M | 40.7% | Unusual | SEC |
| Dec 24, 2020 | Repare Therapeutics Inc. | EVP, Chief Science Officer | Form 4 sale | 57,979 | $1.9M | 40.5% | Unusual | SEC |
| Dec 21, 2020 | Repare Therapeutics Inc. | EVP, Chief Science Officer | Form 4 sale | 40,000 | $1.3M | 31.9% | Unusual | SEC |
| Dec 18, 2020 | Repare Therapeutics Inc. | EVP, Chief Science Officer | Form 4 sale | 17,277 | $604k | 16.9% | Plan not stated | SEC |